Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5013381 | 0.94 | ADORA2A (0.63) | ADORA2AADORA1 | |
| SCHEMBL5011668 | 0.89 | ADORA2A (0.68) | ADORA2AADORA1 | |
| SCHEMBL5012691 | 0.88 | ADORA2A (0.78) | ADORA2AADORA1 | |
| SCHEMBL3548892 | 0.87 | ADORA2A (0.76) | ADORA2A | |
| SCHEMBL5013337 | 0.87 | ADORA2A (0.66) | ADORA2AADORA1 | |
| SCHEMBL5011914 | 0.85 | ADORA2A (0.76) | ADORA2AADORA1 | |
| SCHEMBL3550994 | 0.84 | ADORA2A (0.75) | ADORA2AADORA1 | |
| SCHEMBL5013406 | 0.83 | ADORA2A (0.64) | ADORA2AADORA1 | |
| SCHEMBL5550203 | 0.83 | ADORA2A (0.59) | ADORA2A | |
| SCHEMBL5015039 | 0.83 | ADORA2A (0.61) | ADORA2AADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1633756-B1 | A2A ADENOSINE RECEPTOR ANTAGONISTS | BIOGEN IDEC INC (US) | 2008-12-24 | — | — | EP | claimed |
| US-20070173505-A1 | A2a adenosine receptor antagonists | BIOGEN IDEC MA INC. | 2007-07-26 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070173505-A1 | A2a adenosine receptor antagonists | ADORA2A, ADORA1, ADORA3 | ADORA2A 1/4885ADORA1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.